Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Bristol-Myers Squibb ( (BMY) ) is now available.
On October 30, 2025, Bristol-Myers Squibb announced its financial results for the third quarter of 2025, reporting a 3% increase in total revenues to $12.2 billion, driven by an 18% rise in its Growth Portfolio revenues. The company raised its 2025 revenue guidance to $47.5 billion to $48.0 billion and updated its non-GAAP EPS range to $6.40 to $6.60, reflecting strong business execution and pipeline advancements.
The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.
Bristol-Myers Squibb’s overall stock score reflects strong earnings call performance and reasonable valuation, offset by technical weakness and high leverage. The company’s strategic initiatives and robust growth portfolio are positive, but managing debt and improving profitability remain key challenges.
To see Spark’s full report on BMY stock, click here.
More about Bristol-Myers Squibb
Bristol-Myers Squibb operates in the pharmaceutical industry, focusing on the development of innovative medicines in areas such as oncology, immunology, and cardiovascular diseases. The company is known for its portfolio of immuno-oncology products and aims to deliver transformational medicines to patients worldwide.
Average Trading Volume: 14,412,417
Technical Sentiment Signal: Sell
Current Market Cap: $86.71B
For detailed information about BMY stock, go to TipRanks’ Stock Analysis page.